All sponsors

Hoffmann-La Roche $RO.SW

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS152
PHASE 3 / 2-392
RECRUITING61
READOUTS ≤12 MONTHS36
READOUT SLIPPED >6 MO48%

Delay Index: of 117 active trials registered more than a year ago, 56 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.1 months). See all sponsors →

Open Hoffmann-La Roche on the live radar map → 📅 $RO.SW readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
PASADENA
NCT03100149
P2Active, not recruitingParkinson's Disease3162019-11-27 (+4 mo)
OpRegen
NCT02286089
P1/2Active, not recruitingAge-Related Macular Degeneration242021-12-31 (+65 mo)
COMMODORE 3
NCT04654468
P3Active, not recruitingParoxysmal Nocturnal Hemoglobinuria512022-02-10 (-10 mo)
Giredestrant
NCT04576455
P2Active, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer3032022-02-18
COMMODORE 2
NCT04434092
P3Active, not recruitingParoxysmal Nocturnal Hemoglobinuria2102022-11-16 (+6 mo)
Rainbowfish
NCT03779334
P2Active, not recruitingMuscular Atrophy, Spinal262023-02-20 (+24 mo)
FENopta
NCT05119569
P2Active, not recruitingRelapsing Multiple Sclerosis1092023-03-29 (+4 mo)
HAVEN 7
NCT04431726
P3Active, not recruitingSevere Hemophilia A552023-05-22 (+5 mo)
Alectnib
NCT03456076
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung2572023-06-26
INAVO120
NCT04191499
P2/3Active, not recruitingBreast Cancer3252023-09-29 (-25 mo)
Ocrelizumab
NCT04075266
P2Active, not recruitingMultiple Sclerosis232023-10-05 (+28 mo)
Radiotherapy
NCT05009069
P2Active, not recruitingRectal Neoplasms; Rectal Cancer582023-11-21 (+5 mo)
Mosunetuzumab (IV)
NCT03671018
P1/2Active, not recruitingB-cell Non-Hodgkin Lymphoma4222024-01-30
IMforte
NCT05091567
P3Active, not recruitingSmall-Cell Lung Cancer6602024-07-29 (-7 mo)
REGENCY
NCT04221477
P3Active, not recruitingLupus Nephritis2712024-08-15 (+10 mo)
PADOVA
NCT04777331
P2Active, not recruitingParkinsons Disease5862024-09-11 (+10 mo)
Glofitamab
NCT04980222
P2Active, not recruitingLymphoma462024-10-24 (-2 mo)
MUSETTE
NCT04544436
P3Active, not recruitingMultiple Sclerosis8642024-12-19 (-4 mo)
O'HAND
NCT04035005
P3Active, not recruitingMultiple Sclerosis, Primary Progressive10132025-01-15 (-2 mo)
SUNMO
NCT05171647
P3Active, not recruitingNon-Hodgkin Lymphoma2082025-02-17 (+17 mo)
SKYSCRAPER-14
NCT05904886
P3Active, not recruitingHepatocellular Carcinoma6872025-05-08 (-16 mo)
Operetta 2
NCT05123703
P3Active, not recruitingRelapsing-remitting Multiple Sclerosis1882025-06-09
GAVOTTE
NCT04548999
P3Active, not recruitingMultiple Sclerosis7692025-06-30 (+4 mo)
COMMUTE-p
NCT04958265
P3Active, not recruitingAtypical Hemolytic Uremic Syndrome412025-07-04 (-5 mo)
Giredestrant
NCT04961996
P3Active, not recruitingEarly Breast Cancer41702025-08-08 (-4 mo)
FENhance 2
NCT04586023
P3Active, not recruitingRelapsing Multiple Sclerosis7512025-09-05 (+12 mo)
ALLEGORY
NCT04963296
P3Active, not recruitingSystemic Lupus Erythematosus3032025-09-15 (-2 mo)
FENtrepid
NCT04544449
P3Active, not recruitingMultiple Sclerosis, Primary Progressive9852025-09-17 (+4 mo)
COMMUTE-a
NCT04861259
P3Active, not recruitingAtypical Hemolytic Uremic Syndrome832025-10-09 (+19 mo)
Meteoroid
NCT05271409
P3Active, not recruitingMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)1392025-11-20 (+1 mo)
MAJESTY
NCT04629248
P3Active, not recruitingPrimary Membranous Nephropathy1422025-12-22 (+11 mo)
Atezolizumab
NCT05047250
P3Active, not recruitingNon-Small Cell Lung Cancer602025-12-30 (+21 mo)
FENhance
NCT04586010
P3Active, not recruitingRelapsing Multiple Sclerosis7462026-01-27 (+16 mo)
Giredestrant
NCT04546009
P3Active, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer9922026-01-30 (+21 mo)
ENVOL
NCT06128564
P2Active, not recruitingDuchenne Muscular Dystrophy132026-03-04 (-81 mo)
Tominersen
NCT05686551
P2Active, not recruitingHuntington Disease3012026-05-14 (+16 mo)
Krascendo 1
NCT06497556
P3Active, not recruitingNon-Small Cell Lung Cancer; KRAS G12C Lung Cancer3382026-05-19 (-2 mo)
Celestimo
NCT04712097
P3Active, not recruitingRelapsed or Refractory Follicular Lymphoma4782026-06-03 (-35 mo)
Afimkibart
NCT06863961
P2Active, not recruitingAtopic Dermatitis1622026-07-22 (+2 mo)
GYMINDA
NCT06965413
P2Active, not recruitingObesity; Overweight2852026-09-03 (-2 mo)
PORTAMENTO
NCT07074886
P2Active, not recruitingMultiple Sclerosis1932026-09-17 (-4 mo)
Entrectinib
NCT04603807
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung2172026-09-30 (-4 mo)
IMbrave251
NCT04770896
P3Active, not recruitingUnresectable Hepatocellular Carcinoma5572026-10-14 (+25 mo)
CONSONANCE
NCT03523858
P3Active, not recruitingProgressive Multiple Sclerosis (PMS)9272026-10-22 (+37 mo)
Ametrine-2
NCT06588855
P3Active, not recruitingModerately to Severely Active Ulcerative Colitis3502026-10-29 (-8 mo)
INAVO121
NCT05646862
P3RecruitingBreast Cancer4202026-11-13 (-19 mo)
SHIELD DMD
NCT06450639
P2Active, not recruitingDuchenne Muscular Dystrophy302026-11-18 (+5 mo)
RO7269162
NCT06402838
P2Active, not recruitingAlzheimer's Disease2562026-11-19 (-6 mo)
Atezolizumab
NCT03148418
P3Active, not recruitingCancer3822026-11-30 (-8 mo)
Cielo
NCT05503264
P3Active, not recruitingNMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis1222026-12-16 (+18 mo)
Englumafusp alfa
NCT04077723
P1/2Active, not recruitingLymphoma, Non-Hodgkin4982026-12-28 (+48 mo)
Atezolizumab
NCT05645692
P2Active, not recruitingUrothelial Cancer2042026-12-31
TAHOE
NCT05910528
P2Active, not recruitingCrohns Disease212026-12-31 (+25 mo)
HORIZON 1
NCT05170204
P3Active, not recruitingNon-Small Cell Lung Cancer682027-01-19 (-29 mo)
Ametrine-1
NCT06589986
P3Active, not recruitingModerately to Severely Active Ulcerative Colitis4002027-01-30 (-5 mo)
Ranibizumab
NCT04657289
P3Active, not recruitingNeovascular Age-related Macular Degeneration (nAMD)4512027-02-04 (+40 mo)
CAMMA 2
NCT05535244
P1/2Active, not recruitingMultiple Myeloma902027-02-26 (+3 mo)
Pertuzumab
NCT02320435
P3Active, not recruitingSolid Tumors1542027-03-28 (+27 mo)
Astefania
NCT04873362
P3Active, not recruitingBreast Cancer11882027-03-31 (+15 mo)
SAkuraSun
NCT05199688
P3RecruitingNeuromyelitis Optica Spectrum Disorder; NMOSD82027-03-31 (+32 mo)
Afimkibart
NCT07137598
P2RecruitingRheumatoid Arthritis1602027-04-17 (-3 mo)
COMMODORE 1
NCT04432584
P3Active, not recruitingParoxysmal Nocturnal Hemoglobinuria1902027-04-18 (+69 mo)
Pearlstone
NCT07827599
P3RecruitingInfluenza, Human; Respiratory Tract Infections3252027-04-30
INAVO122
NCT05894239
P3RecruitingMetastatic Breast Cancer2302027-05-03 (-18 mo)
Pebblestone
NCT06094010
P3RecruitingInfluenza11002027-05-11
FENerations1
NCT07161258
P2RecruitingRelapsing Multiple Sclerosis122027-06-08
HUTONG
NCT05562947
P3Active, not recruitingNeovascular Age-related Macular Degeneration; nAMD682027-06-30 (+4 mo)
B-FAST
NCT03178552
P2/3Active, not recruitingNon-Small Cell Lung Cancer10002027-06-30 (+88 mo)
STARTRK-NG
NCT02650401
P1/2Active, not recruitingSolid Tumors; CNS Tumors692027-06-30 (+106 mo)
Atezolizumab
NCT05112965
P3Active, not recruitingNeoplasms492027-06-30 (+19 mo)
RO7247669
NCT04140500
P1/2Active, not recruitingSolid Tumors; Metastatic Melanoma1702027-06-30 (+61 mo)
Astegolimab
NCT05878769
P3Active, not recruitingChronic Obstructive Pulmonary Disease20002027-06-30
Pagoda
NCT04108156
P3Active, not recruitingDiabetic Macular Edema6722027-07-20 (+69 mo)
MORPHEUS-LIVER
NCT04524871
P1/2Active, not recruitingAdvanced Liver Cancers5182027-07-30 (+69 mo)
Inavolisib
NCT07054190
P2RecruitingBreast Cancer1202027-07-31 (+5 mo)
RO7126209
NCT04639050
P1/2Active, not recruitingAlzheimers Disease2412027-07-31 (+34 mo)
ZN-A-1041
NCT05593094
P1/2Active, not recruitingAdvanced Solid Tumors; HER2-positive Breast Cancer2102027-08-31 (+53 mo)
GLOBRYTE
NCT06084936
P3RecruitingLymphoma1822027-08-31 (+19 mo)
ZEBRHA 1
NCT07416526
P3RecruitingHemophilia A1382027-09-23
Glofitamab
NCT06047080
P3Active, not recruitingLarge B-Cell Lymphoma11302027-10-01 (+16 mo)
WILL-EMI
NCT06998524
P3RecruitingVon Willebrand Disease, Type 3752027-10-06 (-2 mo)
IMCODE004
NCT06534983
P2Active, not recruitingMuscle-invasive Urothelial Carcinoma622027-11-10 (-12 mo)
ZYNERGY
NCT07589686
P2Not yet recruitingObesity or Overweight4862027-11-12
OLERO
NCT05269004
P3Active, not recruitingMultiple Sclerosis13002027-12-31 (+24 mo)
Tifeglipron
NCT07112872
P2RecruitingType 2 Diabetes Mellitus3302028-02-05 (+12 mo)
TRONTIER 2
NCT07170150
P3Active, not recruitingAlzheimers Disease10602028-02-16 (-5 mo)
TRONTIER 1
NCT07169578
P3Active, not recruitingAlzheimers Disease11012028-02-16 (-5 mo)
Enicepatide
NCT07670416
P3RecruitingObesity; Overweight3002028-02-24
BOUQUET
NCT04931342
P2Active, not recruitingOvarian Cancer1762028-02-28 (+42 mo)
ZEBRHA 2
NCT07416604
P3RecruitingHemophilia A3602028-02-29
InavoPC
NCT07287150
P2RecruitingMetastatic Castration-Resistant Prostate Cancer1002028-03-31
Obinutuzumab
NCT04408638
P3Active, not recruitingDiffuse Large B-cell Lymphoma2702028-03-31 (+73 mo)
Giredestrant
NCT06065748
P3Active, not recruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer10502028-04-20 (+21 mo)
IMAGINATION
NCT05797610
P3Active, not recruitingPrimary IgA Nephropathy4592028-05-25 (+20 mo)
Mintaka
NCT07282574
P2RecruitingProgressive Multiple Sclerosis3602028-05-30
AMETRINE-SC
NCT07846683
P3RecruitingModerately to Severely Active Ulcerative Colitis3502028-05-31
Phesgo
NCT05296798
P3Active, not recruitingLocally Advanced or Metastatic Breast Cancer9222028-06-15 (+21 mo)
POSTERITY
NCT05039619
P2RecruitingLupus Nephritis402028-06-15 (+39 mo)
Pegozafermin
NCT06419374
P3RecruitingMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis18002028-06-30 (-21 mo)
IMbrella B
NCT03768063
P3Active, not recruitingCancer10002028-07-05 (-6 mo)
Enith1
NCT07351045
P3RecruitingObesity or Overweight20002028-07-24
PLYCOM
NCT05583617
P1/2RecruitingMultiple Myeloma2002028-07-31 (+58 mo)
Enith2
NCT07351058
P3RecruitingObesity or Overweight; Type 2 Diabetes Mellitus16002028-08-07
SOLUNA
NCT07598396
P2RecruitingLupus; Systemic Lupus Erythematosus302028-08-11
ZEBRHA 3
NCT07838194
P3RecruitingHemophilia A502028-09-30
RO7830698
NCT07822334
P1/2RecruitingChronic Obstructive Pulmonary Disease (COPD); Healthy Participants1042028-10-11
ZUPREME-4
NCT07843485
P3RecruitingObesity or Overweight; Type 2 Diabetes6002028-10-20
optINAVO
NCT07368998
P2RecruitingBreast Cancer802028-10-31
CEVOLUTION
NCT07555938
P3RecruitingMultiple Myeloma3802028-10-31
Sightspire
NCT06847542
P3RecruitingNeovascular Age-related Macular Degeneration2502028-11-15 (+4 mo)
Krascendo 2
NCT06793215
P3RecruitingNon-Small Cell Lung Cancer; KRAS G12C Lung Cancer6002028-11-30 (+7 mo)
kalitERA
NCT07827573
P3RecruitingEarly Breast Cancer; Estrogen Receptor-Positive Breast Cancer15002028-11-30
TARBELA-PD
NCT07781644
P2RecruitingParkinson's Disease4742028-12-15
Inavolisib
NCT07405801
P2RecruitingBreast Cancer802028-12-19
ZUPREME-3
NCT07843498
P3RecruitingObesity or Overweight39002028-12-21
SIBERITE-1
NCT06819878
P3RecruitingModerately to Severely Active Crohns Disease6002028-12-31
SIBERITE-2
NCT06819891
P3RecruitingModerately to Severely Active Crohns Disease4252028-12-31
Pegozafermin
NCT06318169
P3RecruitingMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis13502029-02 (+26 mo)
Atezolizumab
NCT04712643
P3Active, not recruitingHepatocellular Carcinoma3422029-02-01 (+47 mo)
Glofitamab
NCT03075696
P1/2Active, not recruitingNon-Hodgkin's Lymphoma9402029-03-30
ENI-SPIRE-2
NCT07889648
P3Not yet recruitingType 2 Diabetes Mellitus9482029-04-02
Cevostamab
NCT07825064
P2RecruitingMultiple Myeloma452029-04-13
BREnnA
NCT07413939
P2/3RecruitingHER2-positive Breast Cancer6502029-05-01
Giredestrant
NCT04802759
P1/2RecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer3162029-05-30 (+31 mo)
Inavolisib
NCT07748208
P2RecruitingBreast Cancer; Diabetes Type II402029-06-15
PARAISO
NCT07174310
P3RecruitingParkinson's Disease9002029-06-30
Obinutuzumab
NCT06806033
P2RecruitingRelapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma1302029-07-31 (+28 mo)
Operetta III
NCT07503340
P2Not yet recruitingRelapsing-remitting Multiple Sclerosis252029-08-31
TARBELA-AD
NCT07781657
P2RecruitingAlzheimer's Disease4502029-11-01
iMATRIX GLO
NCT05533775
P1/2RecruitingMature B-Cell Non-Hodgkin Lymphoma652029-11-30 (+26 mo)
Fenebrutinib
NCT07937852
P3Not yet recruitingMultiple Sclerosis18002029-11-30
OleroMAX
NCT06675955
P3RecruitingMultiple Sclerosis5002029-12-31
Portal
NCT03683251
P3RecruitingNeovascular Age-Related Macular Degeneration10002029-12-31 (+90 mo)
AMETRINE-PEDS
NCT07158242
P3RecruitingModerately to Severely Active Ulcerative Colitis1002030-03-31
SIBERITE-PEDS
NCT07298421
P3RecruitingModerately to Severely Active Crohns Disease1002030-05-31
ZUPREME-5
NCT07843472
P3RecruitingObesity or Overweight; Cardiovascular Disease25002030-07-28
Mosunetuzumab (IV)
NCT04246086
P1/2Active, not recruitingFollicular Lymphoma2372030-09-06 (+98 mo)
Morpheus-panBC
NCT03424005
P1/2RecruitingMetastatic Breast Cancer11322030-09-30 (+110 mo)
Enith-MACE
NCT07918846
P3Not yet recruitingOverweight; Obesity82002031-03-20
KRAScendo 170
NCT05789082
P1/2RecruitingNon-Small Cell Lung Cancer3202032-01-29 (+76 mo)
KRASCENDO 3
NCT07541170
P3RecruitingNon-small Cell Lung Cancer4002032-01-31
INAVO123
NCT06790693
P3RecruitingBreast Cancer4502032-01-31 (+48 mo)
Alectinib
NCT04774718
P1/2Active, not recruitingALK Fusion-positive Solid or CNS Tumors422032-02-28 (+56 mo)
SPK-8011QQ
NCT07226206
P1/2RecruitingHemophilia A52032-04-30 (+15 mo)
PrevenTRON
NCT07717411
P3RecruitingAlzheimer's Disease16002032-07-30
Entrectinib
NCT04589845
P2Active, not recruitingSolid Tumors9202032-09-25
Velarite-LTE
NCT07223697
P2Active, not recruitingAtopic Dermatitis1202033-03-01
UmbrellaMAX
NCT05862285
P3RecruitingCancer2002033-03-01 (-2 mo)
dRAvite-LTE
NCT07620392
P2RecruitingRheumatoid Arthritis1202033-07-08
NXT007
NCT05987449
P1/2RecruitingHemophilia A602033-12-11 (+18 mo)
SPK-10001
NCT06826612
P1/2RecruitingHuntington Disease532035-01-12
TRAVELLER
NCT07177352
P3RecruitingAlzheimers Disease800002035-07-31